Supported by the research award 2020 of the Association of Rhine-Westphalian Ophthalmologists (RWA) to MP, the German Research Foundation (DFG) grant PF950/1-1 to MP; a BrightFocus Foundation grant M2019155 to J.A.H., an Unrestricted Grant for Research to Prevent Blindness and a P30 Core Grant for Vision Research (2P30EY001792), Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL (J.A.H., J.I.L.); and in part by Novartis Pharma GmbH, Germany (M.F.) and Unrestricted Grant from Research to Prevent Blindness, New York, NY, to the Department of Ophthalmology & Visual Sciences, University of Utah; and in part by an Unrestricted Grant from Research to Prevent Blindness, New York, NY, to the Department of Ophthalmology, Byers Eye Institute at Stanford, Stanford University School of Medicine and NIH grant P30-EY026877.
Disclosure: M. Pfau, Heidelberg Engineering (F), Optos (F), Carl Zeiss Meditec (F), CenterVue (F); S. Sahu, None; R.A. Rupnow, None; K. Romond, None; D. Millet, Heidelberg Engineering (F), Optos (F), Carl Zeiss Meditec (F), CenterVue (F); F.G. Holz, Acucela (R), Allergan (R), Apellis (R), Bayer (R), Bioeq/Formycon (R), CenterVue (R), Ellex (R), Roche/Genentech (R), Geuder (R), Kanghong (R), NightStarx (R), Novartis (R), Optos (R), Zeiss (R), Acucela (C), Allergan (C), Apellis (C), Bayer (C), Boehringer-Ingelheim (C), Roche/Genentech (C), Geuder (C), Grayburg Vision (C), LinBioscience (C), Kanghong (C), Novartis (C), Pixium Vision (C), Oxurion (C), Stealth BioTherapeutics (C), Zeiss (C); S. Schmitz-Valckenberg, Acucela/ Kubota Vision (F), Apellis (C), Novartis (C, F, R), Allergan (C, F, R), Bayer (F, R), Bioeq/Formycon (F, C), Carl Zeiss MedicTec (F, R), CenterVue (F), Galimedix (C), Roche (F, R), Heidelberg Engineering (F), Katairo (F), Optos (F), Oxurion (C), Roche/Genentech (F,C); M. Fleckenstein, Heidelberg Engineering (F, C), Optos (F), Carl Zeiss Meditec (F), Genentech/Roche (F, C), CenterVue (F), Novartis (F, C) US20140303013 (P); J.I. Lim, Genentech (F), Regeneron (F), Allergan (R), Alcon (R), Opthea (C), Santen (C), Quark (C), Aura Biosciences (C), Iveric Bio (R), Cognition (C), Aldeyra (F), Novartis (C), Graybug (F), Stealth (F), Chengdu (F); L. de Sisternes, Carl Zeiss Meditec (E); T. Leng, Kodiak (F), 3T (F), Genentech (C), Regeneron (C), Verana (C); D.L. Rubin, None; J.A. Hallak, BrightFocus Foundation Grant (R)